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Dear Sir, 
In the July 2011 issue Michael Elashoff and colleagues 1 reported an increased incidence of 
pancreatitis in diabetic subjects undergoing glucagon-like peptide (GLP)-1-based therapies. In 
light of the recently emerged and proliferating discussion about the clinical use and the 
associated risks of incretin-based therapies we would like to comment on this article and 
contribute evidence supporting the role of adipose-derived dipeptidyl peptidase (DPP)-4 in the 
context of the metabolic syndrome.  
DPP-4 is found in many different tissues as a membrane-associated peptidase but also exists 
as a soluble form in plasma of humans and rodents. It cleaves and thereby inhibits GLP-1, 
which is secreted postprandially by intestinal L-cells to improve clearance of glucose from 
circulation (incretin effect). Several DPP-4 inhibitors are currently used to treat type 2 
diabetes 2. Recently, Daniela Lamers and colleagues 3 reported in the May 20th issue of 
Diabetes that adipocytes release DPP-4 into circulation, an observation that defines DPP-4 as 
an adipokine. We observed significant changes in the abundance of adipokines in supernatants 
collected from 3T3-L1 adipocytes cultured for 18 hours in the presence of the DPP-4 inhibitor 
(DPP-4i) sitagliptin. Among four different adipokines analysed adiponectin was increased 
(1.2 fold ± 0.07, p < 0.05, n=4) while MCP-1 and leptin remained unchanged. The increased 
accumulation of adiponectin in the presence DPP-4i is in line with the finding of Lamers and 
colleagues who described a negative correlation between the secretion of DPP-4 and 
adiponectin. In our experimental setting, we also found higher level of IL-6 (1.6 fold ± 0.06, p 
< 0.05, n=4) in the presence of DPP-4i. That DPP-4i promotes accumulation of a pro-
inflammatory cytokine, however, supports the finding by Michael Elashoff and colleagues. 
Given the association between low-grade systemic inflammation and the development of type 
2 diabetes an important yet unanswered question is if DPP-4 secreted by adipocytes is pro- or 
anti-inflammatory? As a caveat, however, it should be noted that our results were obtained 
with 3T3-L1 adipocytes in vitro and might not reflect the more complex in vivo situation. 
Conclusive analysis of the physiological role of DPP-4 production by adipocytes, especially 
with a focus on its established interaction with cytokines and chemokines, appears desirable 
to ensure save therapeutic use of DPP-4 inhibitors in the treatment of hyperglycaemia and 
type 2 diabetes.  
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